Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Assets (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Non-Current Assets for 11 consecutive years, with $88.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 12.18% to $88.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $374.0 million through Dec 2025, down 32.68% year-over-year, with the annual reading at $88.8 million for FY2025, 12.18% down from the prior year.
  • Non-Current Assets hit $88.8 million in Q4 2025 for Seres Therapeutics, down from $91.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $183.2 million in Q4 2023 to a low of $37.5 million in Q3 2021.
  • Historically, Non-Current Assets has averaged $105.1 million across 5 years, with a median of $96.6 million in 2025.
  • Biggest five-year swings in Non-Current Assets: soared 200.64% in 2022 and later plummeted 44.85% in 2025.
  • Year by year, Non-Current Assets stood at $51.2 million in 2021, then skyrocketed by 200.64% to $154.0 million in 2022, then grew by 18.94% to $183.2 million in 2023, then crashed by 44.79% to $101.1 million in 2024, then fell by 12.18% to $88.8 million in 2025.
  • Business Quant data shows Non-Current Assets for MCRB at $88.8 million in Q4 2025, $91.9 million in Q3 2025, and $95.1 million in Q2 2025.